Intellia Therapeutics Inc NTLA
$12.84 $0.40 (3.22%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
NTLA Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Intellia Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Intellia Therapeutics Inc. Stock Analysis NTLA
United States Health Care Small Cap Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 377 full-time employees. The company went IPO on 2016-05-06. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The firm is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. The company is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
Intellia Therapeutics Inc (NTLA) Chart
Financial Metrics & Statements of Intellia Therapeutics Inc (NTLA)
FAQ's for Intellia Therapeutics Inc (NTLA)
- As of August 2026, Intellia Therapeutics Inc NTLA is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Intellia Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Intellia Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Intellia Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Intellia Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Intellia Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Intellia Therapeutics Inc (NTLA)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
